Oct 17, 2019
Outcomes of the AIFA's pricing and reimbursement committee published
On October 4, 2019, the Italian Drugs Agency (AIFA) has published outcomes of the meeting of their pricing and reimbursement committee (CPR) held on September 24-26, 2019.

The CPR brought many decisions for single medicines, but also made some price-volume agreements.

The possible outcomes of the CPR meeting are:
  • Istruttoria CPR: Further information is requested from other commissions, AIFA experts, public administration, or the manufacturer. In case of requiring more information from the manufacturer, the procedure is paused until the answers are provided;
  • Convocazione CPR: The manufacturer is contacted to meet to finalize the contract;
  • Approfondimento CTS: The scientific-technical commission is asked to review the case;
  • Procedura conclusa: CPR made a final decision, or the procedure is completed without a need for further administrative steps / communication to the manufacturer;
  • CdA: The CPR has taken the decision, and the case is forwarded to the AIFA Board of Directors.
The CPR meetings are held each month.

The document contains eight pages of outcomes (for >60 drugs) of the CPR assessment and can be seen here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)